However, although the effects of PD-L1 antibody on IFN-γ production seem to be profound, it still remains speculative whether the blockade of PD-1/PD-L1 by PD-L1 antibody will be sufficient for tumor regression in vivo. The gene discussed is IFNG; the disease is neoplasm.